NF EN ISO 25539-2
Cardiovascular implants - Endovascular devices - Part 2 : vascular stents
ISO 25539-2:2008 specifies requirements for vascular stents, based upon current medical knowledge. With regard to safety, it gives requirements for intended performance, design attributes, materials, design evaluation, manufacturing, sterilization packaging and information supplied by the manufacturer. It should be considered as a supplement to ISO 14630, which specifies general requirements for the performance of non-active surgical implants.The scope of ISO 25539-2:2008 includes vascular stents used to treat vascular lesions or stenoses, or other vascular abnormalities. These devices might or might not incorporate surface modifications of the stent such as drug and/or other coatings. Stents covered with materials that significantly modify the permeability of the uncovered stent are within the scope of ISO 25539-1:2003. The stent design might dictate the need to address functional requirements identified in both ISO 25539-1:2003 and ISO 25539-2:2008.Delivery systems are included in ISO 25539-2:2008 if they comprise an integral component of the deployment of the vascular stent.Some pharmacological aspects of drug eluting stents are addressed in ISO 25539-2:2008, but this document is not comprehensive with respect to the pharmacological evaluation of drug eluting stents.With the exception of sterilization, ISO 25539-2:2008 does not address requirements for the evaluation of animal tissue products.
ISO 25539-2:2008 specifies requirements for vascular stents, based upon current medical knowledge. With regard to safety, it gives requirements for intended performance, design attributes, materials, design evaluation, manufacturing, sterilization packaging and information supplied by the manufacturer. It should be considered as a supplement to ISO 14630, which specifies general requirements for the performance of non-active surgical implants.
The scope of ISO 25539-2:2008 includes vascular stents used to treat vascular lesions or stenoses, or other vascular abnormalities. These devices might or might not incorporate surface modifications of the stent such as drug and/or other coatings. Stents covered with materials that significantly modify the permeability of the uncovered stent are within the scope of ISO 25539-1:2003. The stent design might dictate the need to address functional requirements identified in both ISO 25539-1:2003 and ISO 25539-2:2008.
Delivery systems are included in ISO 25539-2:2008 if they comprise an integral component of the deployment of the vascular stent.
Some pharmacological aspects of drug eluting stents are addressed in ISO 25539-2:2008, but this document is not comprehensive with respect to the pharmacological evaluation of drug eluting stents.
With the exception of sterilization, ISO 25539-2:2008 does not address requirements for the evaluation of animal tissue products.
Le présent document prescrit les exigences spécifiques relatives aux endoprothèses artérielles et aux prothèses endovasculaires et à leur mise en place en vue de corriger ou de compenser un défaut sur une artère. En ce qui concerne la sécurité, et en complément de la EN ISO 14630 et de la EN 12006-3, le présent document présente les exigences spécifiques relatives aux performances prévues, aux attributs de la conception, aux matériaux, à l'évaluation de la conception, à la fabrication, à la stérilisation, à l'emballage et aux informations fournies par le fabricant. Le présent document s'applique aux endoprothèses artérielles et aux prothèses endovasculaires pour l'aorte, les segments cervicaux des artères à destinée encéphalique, les artères coronaires, les artères intra-cérébrales, les artières périfiphériques, les artères pulmonaires, les artères viscérales et les troncs supra-aortiques. Le présent document concerne également les prothèses endovasculaires utilisées pour le traitement des anévrismes, des sténoses artérielles ou de toute autre anomalie vasculaire. À signaler également que : - les systèmes de largage sont également inclus s'ils comportent un composant intégral de l'implant ; - les endoprothèses artérielles couvertes utilisées comme systèmes d'occlusion sont incluses.
ISO 25539-2:2008 specifies requirements for vascular stents, based upon current medical knowledge. With regard to safety, it gives requirements for intended performance, design attributes, materials, design evaluation, manufacturing, sterilization packaging and information supplied by the manufacturer. It should be considered as a supplement to ISO 14630, which specifies general requirements for the performance of non-active surgical implants. The scope of ISO 25539-2:2008 includes vascular stents used to treat vascular lesions or stenoses, or other vascular abnormalities. These devices might or might not incorporate surface modifications of the stent such as drug and/or other coatings. Stents covered with materials that significantly modify the permeability of the uncovered stent are within the scope of ISO 25539-1:2003. The stent design might dictate the need to address functional requirements identified in both ISO 25539-1:2003 and ISO 25539-2:2008. Delivery systems are included in ISO 25539-2:2008 if they comprise an integral component of the deployment of the vascular stent. Some pharmacological aspects of drug eluting stents are addressed in ISO 25539-2:2008, but this document is not comprehensive with respect to the pharmacological evaluation of drug eluting stents. With the exception of sterilization, ISO 25539-2:2008 does not address requirements for the evaluation of animal tissue products.
- Avant-proposiv
- Introductionv
-
1 Domaine d'application1
-
2 Références normatives2
-
3 Termes et définitions2
-
4 Exigences générales5
-
4.1 Classification5
-
4.2 Taille5
-
4.3 Définition de l'utilisation clinique prévue5
-
5 Performances attendues6
-
6 Attributs de conception6
-
7 Matériaux8
-
8 Évaluation de la conception8
-
9 Pharmacovigilance35
-
10 Fabrication35
-
11 Stérilisation35
-
12 Emballage36
- Annexe A (informative) Caractéristiques des dispositifs endovasculaires - Stents vasculaires - Considérations techniques et cliniques40
- Annexe B (informative) Essais in vitro et essais analytiques49
- Annexe C (informative) Définition des événements cliniques à déclaration obligatoire53
- Annexe D (informative) Méthodes d'essai56
- Annexe E (informative) Informations complémentaires sur l'approche analytique employée lors de l'essai de durabilité à la fatigue98
- Bibliographie101
At a glance, you will be able to identify the additions, deletions or modifications to a text, table, figure and formula.

The Redlines + service is offered to you on the collection of French standards in force, in French language and in HTML and PDF format.
For an overview of the service, click on View a standard in redline format
COBAZ is the simple and effective solution to meet the normative needs related to your activity, in France and abroad.
Available by subscription, CObaz is THE modular solution to compose according to your needs today and tomorrow. Quickly discover CObaz!
Request your free, no-obligation live demo
I discover COBAZ